Therefore, this clinical trial was based on the use of HLA-A2402–restricted CTL epitopes derived from four glioma oncoantigens (GOAs) that we and others observed to be highly expressed in HGGs [23,24,25,26]: Lymphocyte antigen 6 family member K (LY6K), DEP domain containing 1 (DEPDC1), kinesin family member 20A (KIF20A), and forkhead box M1 (FOXM1)—in addition to two glioma angiogenesis-associated antigen (GAAAs): VEGFR1 and VEGFR2 [27,28]. This evidence concerns the gene LY6K and glioma.